Cannabix Technologies said it has delivered multiple Cannabix Marijuana Breath Test (MBT) units to Omega Laboratories to initiate phased commercialization efforts.
The MBT hardware includes Cannabix’s proprietary Breath Collection Unit (BCU) and Breath Cartridges (BC) technology which are designed to collect and preserve breath samples to be analyzed with Omega’s Laboratory Developed Test Method to detect delta-9-tetrahydrocannabinol (Δ9-THC), the primary psychoactive component of cannabis, in breath.
The MBT is focused on “recent use” detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption).
Cannabix and Omega are working together to implement the MBT with select key clients and undertake a phased ramp-up to meet demand. Furthermore, the delivery of the initial units will support the coordination and the integration of breath testing (using Cannabix Breath Cartridges) into Omega’s suite of services and lab testing protocols. The parties are working together on manufacturing, marketing, distribution, support and logistics for the MBT. With the current shipment Cannabix has delivered 200 Breath Cartridges and several BCUs.
Earlier in the year, Omega delivered a Validation Packet for Omega’s Laboratory Developed Test Method to test delta9 THC analytes. The Validation Packet was performed in Omega’s ISO/IEC 17025 accredited laboratory environment utilizing their well recognized Quality Management System.
